English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Over 80% of clinical obstetricians have reported prescribing 17-OHPC for the prevention of preterm birth [3]. Disappointingly, the surveyed physicians reported that there was about half of eligible patients seen in their practice but not prescribed 17-OHPC [3], and the financial and logistical barriers carried the most weight (approximately 75%) in the decision not to prescribe FDAapproved 17-OHPC to an eligible patient [4]. Additionally, thirty-nine percent of respondents had professional liability concerns regarding prescribing compounded 17-OHPC.

journal of pharmaceutics and drug development

Pharmacy Compounding Quality Control and Pharmaceutical Development Strategies for Seventeen alpha Hydroxyprogesterone Caproate in Prevention of Preterm Delivery